Crizanlizumab-tmca 100 mg in 10 mL Injection
RxNorm 2262425

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2262425 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: crizanlizumab-tmca 100 mg in 10 mL Injection.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCD
10 mL crizanlizumab-tmca 10 mg/ML Injection
Primary clinical definition
AUI:11801084
View
PSN
Crizanlizumab-tmca 100 mg in 10 mL Injection
AUI:11801098
View
SY
Crizanlizumab-tmca 100 mg per 10 mL Injection
AUI:11801097
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCDPrescribable

Semantic Clinical Drug (SCD):
10 mL crizanlizumab-tmca 10 mg/ML Injection
(Atom ID: 11801084)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
10 ML crizanlizumab-tmca 10 MG/ML Injection
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2262425
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11801084
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCD
Semantic Clinical Drug (Ingredient + Strength + Dose Form)
Source Code
2262425
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
May 04, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{2262422} 2262279
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{2262422} 2262279
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH
10 MG/ML (expressed as crizanlizumab-tmca)
Available drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM
{2262422} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUG
US
Drug available for use in Humans
RXN QUANTITY
10 ML
Normal Form quantity factor
PSNPrescribable

Prescribable Name (PSN):
Crizanlizumab-tmca 100 mg in 10 mL Injection
(Atom ID: 11801098)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
crizanlizumab-tmca 100 MG in 10 ML Injection
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2262425
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11801098
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2262425
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
May 04, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SYPrescribable

Synonym (SY):
Crizanlizumab-tmca 100 mg per 10 mL Injection
(Atom ID: 11801097)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
crizanlizumab-tmca 100 MG per 10 ML Injection
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2262425
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
11801097
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2262425
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
May 04, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Crizanlizumab-tmca Injection


Crizanlizumab-tmca injection is used to reduce the number of pain crises (sudden, severe pain that may last several hours to several days) in adults and children 16 years of age and older with sickle cell disease (an inherited blood disease). Crizanlizumab-tmca is in a class of medications called monoclonal antibodies. It works by blocking certain blood cells from interacting.
[Learn More]


* Please review the disclaimer below.